Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank Robert H. Brown Jr. and Jonathan Glass for their contributions to the data collected here. The authors would also like to acknowledge the ALS association, ALS Therapy Alliance, and, most importantly, our patients, for supporting the biomarker trials which were used as the dataset for this manuscript.

Christina Fournier is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health.

Declaration of interest: Nazem Atassi has acted as a consultant to Biogen Idec, a paid speaker for Oakstone Publishing, and receives research funding from the Muscular Dystrophy Association, ALS Association, American Academy of Neurology, and ALS Therapy Alliance.

Robert Bowser is co-Founder of Knopp Biosciences, LLC and Iron Horse Diagnostics Inc., biotechnology companies focused on developing diagnostics and therapeutics for ALS and other neurologic disorders.

Merit Cudkowicz, in the past two years, has served as a consultant for Teva Pharmaceuticals, Millenium, and Trophos (Data and Safety Monitoring Board) and has served on an advisory board for Biogen Idec, Inc.

David Lacomis receives research funding from Biogen Idec and ATA.

James Berry has acted as a consultant to Biogen Idec, a paid speaker for Oakstone Publishing, and receives research funding from the Muscular Dystrophy Association, ALS Association, American Academy of Neurology, and ALS Therapy Alliance.

The authors alone are responsible for the content and writing of the paper.